Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: A multicenter, randomized DECOG trial.
Ulrike Leiter(University of Tübingen), Claus Garbe(University of Tübingen), Rudolf Herbst(Helios Klinikum Erfurt), Ulrike Keim, Cord Sunderkötter(MSB Medical School Berlin), Carola Berking(Universitätsklinikum Erlangen), Cornelia Mauch(University Hospital Cologne), Norbert H. Brockmeyer(Deutsches Bergbau-Museum Bochum), Thomas Vogt(University Dermatology), Martin Kaatz(SRH Wald-Klinikum Gera), Werner Hohenberger(Universitätsklinikum Erlangen), K.W. Schulte(Heinrich Heine University Düsseldorf), Percy Lehmann(Helios Universitätsklinikum Wuppertal), Jan‐Christoph Simon(Leipzig University), Rudolf Stadler(University Hospitals of the Ruhr-University of Bochum), Jens Ulrich, Wolfgang Gehring(Städtisches Klinikum Karlsruhe)
Cited by 18
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Evaluating the public health impact of health promotion interventions: the RE-AIM framework.
|American Journal of Public Health|1999|7.2k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k